"Entera Bio Reveals Promising Phase 2 Results for Oral Osteoporosis Therapy"

Entera Bio Ltd. announced promising Phase 2 results for its oral PTH tablet, EB613, demonstrating significant improvements in bone density for postmenopausal women at high risk for bone fracture.

• At the North American Menopause Society Annual Meeting, Entera Bio revealed that EB613, an oral tablet (pharmacy) containing parathyroid hormone, significantly improved bone density in postmenopausal women.
• The Phase 2 trial results showed that EB613 enhanced bone density at the femoral neck, crucial for reducing the risk of bone fracture in women suffering from osteoporosis.
• This innovative peptide therapy aims to stimulate anabolism in bone tissue, offering a potentially effective treatment for postmenopausal women facing the challenges of osteoporosis.